Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Saulino

Physical Medicine & Rehabilitation Elkins Park, PA Medical Doctor

NPI 1821178484 CMS profile 174063

60 Township Line Rd, Elkins Park, PA 19027

Open in the dashboard

General payments

$424,513

392 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$77,376 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Michael Saulino of Elkins Park, PA is reported in the CMS Open Payments database as having received $424,513 across 392 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $77,376 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Physical Medicine & Rehabilitation profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $100,141 91
2024 General $95,569 85
2023 General $70,518 66
2022 General $69,095 51
2021 General $32,563 23
2020 General $34,092 33
2019 General $22,535 43

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Saulino
  • Physical Medicine & Rehabilitation median
  • Middle half of Physical Medicine & Rehabilitation
  • National median

In program year 2025, general payments to Michael Saulino were reported at $100,141. Among 4,146 Physical Medicine & Rehabilitation profiles paid that year, the median was $139 and the middle half received between $48 and $410.

Show as a table
Year Michael Saulino Physical Medicine & Rehabilitation median Middle half National median
2019 $22,535 $133 $45–$390 $163
2020 $34,092 $88 $29–$272 $114
2021 $32,563 $116 $33–$360 $132
2022 $69,095 $123 $40–$378 $149
2023 $70,518 $131 $43–$396 $160
2024 $95,569 $141 $45–$409 $164
2025 $100,141 $139 $48–$410 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Ipsen Biopharmaceuticals, Inc $361,749 212 payments
  2. Medtronic USA, Inc. $19,143 30 payments
  3. TerSera Therapeutics LLC $8,772 29 payments
  4. AbbVie, Inc. $8,028 24 payments
  5. Medtronic, Inc. $8,020 36 payments
  6. Piramal Critical Care $6,191 13 payments
  7. SPR Therapeutics, Inc $4,369 4 payments
  8. Pacira Pharmaceuticals Incorporated $4,037 18 payments
  9. Amneal Pharmaceuticals LLC $2,826 4 payments
  10. Sandoz Inc. $477 1 payment
  11. Other $901 21 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $294,775 86 payments
  2. Consulting Fee $49,030 40 payments
  3. Travel and Lodging $37,190 101 payments
  4. Honoraria $28,945 8 payments
  5. Food and Beverage $14,573 157 payments
Products named General payments · program years 2019–2025
  1. DYSPORT $361,749 212 payments
  2. SYNCHROMED $11,957 22 payments
  3. Prialt $6,632 23 payments
  4. LIORESAL $6,262 4 payments
  5. SYNCHROMEDII $5,289 21 payments
  6. SPRINT PNS System $4,369 4 payments
  7. BOTOX $4,046 12 payments
  8. GABLOFEN Pharmacology $3,168 4 payments
  9. GABLOFEN Pharmacology $3,168 4 payments
  10. GABLOFEN Pharmacology $3,168 4 payments
  11. Other $25,425 99 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 32 drugs

Part D claims

1,392

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$167,499

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

18.3%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycontin Oxycodone Hcl Brand 83 $122,662
Oxycodone Hcl Generic 268 $10,523
Morphine Sulfate Er Morphine Sulfate Brand 70 $9,160
Hydromorphone Hcl Generic 41 $3,282
Lidocaine Generic 14 $2,927
Gabapentin Generic 118 $2,641
Morphine Sulfate Generic 35 $2,227
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 75 $2,206
Baclofen Generic 44 $1,618
Methadone Hcl Generic 33 $1,536

The 10 drugs with the highest cost, of 32 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 25 billing codes

Paid by Medicare

$56,717

Medicare's payments for the services billed

Medicare patients

136

Average age 65

Services billed

2,655

71 women, 65 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 63%
Depression 44%
Ischemic heart disease 34%
Diabetes 27%
COPD 24%
Chronic kidney disease 21%
Osteoporosis 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DYSPORT
  • Ipsen Biopharmaceuticals, Inc $84,496
$84,496 — —
BOTOX
  • AbbVie, Inc. $3,523
$3,523 — —
Prialt
  • TerSera Therapeutics LLC $2,471
$2,471 — —
Zilretta
  • Pacira Pharmaceuticals Incorporated $948
$948 — —
Xeomin
  • Merz Pharmaceuticals, LLC $125
$125 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

392 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physical Medicine & Rehabilitation in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record